×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TGTX – tg therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TGTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/10
08:12 am
tgtx
BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX) [Yahoo! Finance]
Low
Report
BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX) [Yahoo! Finance]
3/9
12:35 pm
tgtx
Is TG Therapeutics (TGTX) Pricing Reflecting Its Mixed Multi Year Share Performance? [Yahoo! Finance]
Low
Report
Is TG Therapeutics (TGTX) Pricing Reflecting Its Mixed Multi Year Share Performance? [Yahoo! Finance]
3/9
07:58 am
tgtx
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis [Yahoo! Finance]
Low
Report
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis [Yahoo! Finance]
3/9
07:30 am
tgtx
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
Low
Report
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
3/9
03:34 am
tgtx
Azer Cel Milestone Broadens TG Therapeutics Autoimmune Pipeline And Valuation Story [Yahoo! Finance]
Low
Report
Azer Cel Milestone Broadens TG Therapeutics Autoimmune Pipeline And Valuation Story [Yahoo! Finance]
3/8
04:33 pm
tgtx
How Investors Are Reacting To TG Therapeutics (TGTX) Adding Azer-cel Milestone to Its MS Portfolio [Yahoo! Finance]
Low
Report
How Investors Are Reacting To TG Therapeutics (TGTX) Adding Azer-cel Milestone to Its MS Portfolio [Yahoo! Finance]
3/8
01:33 pm
tgtx
Assessing TG Therapeutics (TGTX) Valuation After BRIUMVI-Led Earnings And Autoimmune Pipeline Updates [Yahoo! Finance]
Low
Report
Assessing TG Therapeutics (TGTX) Valuation After BRIUMVI-Led Earnings And Autoimmune Pipeline Updates [Yahoo! Finance]
3/8
06:33 am
tgtx
Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings [Yahoo! Finance]
Low
Report
Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/27
05:05 pm
tgtx
Form 10-K TG THERAPEUTICS, INC. For: Dec 31
Low
Report
Form 10-K TG THERAPEUTICS, INC. For: Dec 31
2/26
07:08 am
tgtx
Form 8-K TG THERAPEUTICS, INC. For: Feb 26
High
Report
Form 8-K TG THERAPEUTICS, INC. For: Feb 26
1/29
05:25 pm
tgtx
Form 4 TG THERAPEUTICS, INC. For: Jan 28 Filed by: Charney Laurence N
Low
Report
Form 4 TG THERAPEUTICS, INC. For: Jan 28 Filed by: Charney Laurence N
1/13
04:28 pm
tgtx
Form 8-K TG THERAPEUTICS, INC. For: Jan 13
Medium
Report
Form 8-K TG THERAPEUTICS, INC. For: Jan 13
1/9
05:16 pm
tgtx
Form 4 TG THERAPEUTICS, INC. For: Jan 08 Filed by: WEISS MICHAEL S
Low
Report
Form 4 TG THERAPEUTICS, INC. For: Jan 08 Filed by: WEISS MICHAEL S
1/9
05:15 pm
tgtx
Form 4 TG THERAPEUTICS, INC. For: Jan 08 Filed by: Power Sean A
Low
Report
Form 4 TG THERAPEUTICS, INC. For: Jan 08 Filed by: Power Sean A
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/8
TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition
24.6%
12/23 TG Therapeutics Announces $50.0 Million Registered Direct Public Offering of Common Stock to a Single Institutional Investor 15.9%
6/26 TG Therapeutics: Hitting A Growth Inflection [Seeking Alpha] 14.3%
10/28 TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma 13.2%
4/18 TG Therapeutics Inc (NASDAQ: TGTX) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $25.00 price target on the stock. 8.9%
6/18 TG Therapeutics to Present at the Raymond James Life Sciences and MedTech Conference 7.5%
3/20 Form 424B5 TG THERAPEUTICS, INC. 7.3%
4/17 TG Therapeutics Inc (NASDAQ: TGTX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 6.5%
8/29 TG Therapeutics Announces Data Presentations at the Upcoming 35th Annual Congress of ECTRIMS 5.4%
11/8 TG Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results and Business Update 5.1%
12/23 TG Therapeutics Announces $50.0 Million Registered Direct Public Offering of Common Stock to a Single Institutional Investor 15.9%
6/26 TG Therapeutics: Hitting A Growth Inflection [Seeking Alpha] 14.3%
10/28 TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma 13.2%
4/18 TG Therapeutics Inc (NASDAQ: TGTX) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $25.00 price target on the stock. 8.9%
6/18 TG Therapeutics to Present at the Raymond James Life Sciences and MedTech Conference 7.5%
3/20 Form 424B5 TG THERAPEUTICS, INC. 7.3%
4/17 TG Therapeutics Inc (NASDAQ: TGTX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 6.5%
8/29 TG Therapeutics Announces Data Presentations at the Upcoming 35th Annual Congress of ECTRIMS 5.4%
11/8 TG Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results and Business Update 5.1%
TOP News Decliners
3/14
TG Therapeutics Inc (NASDAQ: TGTX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating.
-16.5%
3/7 TG Therapeutics Inc (NASDAQ: TGTX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. -15.1%
5/10 Form 10-Q TG THERAPEUTICS, INC. For: May 10 -9.4%
12/6 TG Therapeutics Recaps Schedule of Triple Therapy Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition -8.5%
5/7 TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 71st Annual Meeting -8.0%
8/22 TG Therapeutics Inc (NASDAQ: TGTX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.2%
5/10 Q1/2019 3/31/2019 EPS -0.430 ZacksConsensus -0.470 ActVsEst 0.040 - Beat -6.8%
1/17 TG Therapeutics Inc (NASDAQ: TGTX) had its price target raised by analysts at HC Wainwright from $20.00 to $24.00. They now have a "buy" rating on the stock. -5.8%
9/5 Form S-3ASR TG THERAPEUTICS, INC. -5.7%
9/20 TG Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference -5.6%
3/7 TG Therapeutics Inc (NASDAQ: TGTX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. -15.1%
5/10 Form 10-Q TG THERAPEUTICS, INC. For: May 10 -9.4%
12/6 TG Therapeutics Recaps Schedule of Triple Therapy Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition -8.5%
5/7 TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 71st Annual Meeting -8.0%
8/22 TG Therapeutics Inc (NASDAQ: TGTX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.2%
5/10 Q1/2019 3/31/2019 EPS -0.430 ZacksConsensus -0.470 ActVsEst 0.040 - Beat -6.8%
1/17 TG Therapeutics Inc (NASDAQ: TGTX) had its price target raised by analysts at HC Wainwright from $20.00 to $24.00. They now have a "buy" rating on the stock. -5.8%
9/5 Form S-3ASR TG THERAPEUTICS, INC. -5.7%
9/20 TG Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: